Skip to search formSkip to main contentSkip to account menu

Teceleukin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Japanese patients with neuroblastoma completing induction therapy and high-dose chemotherapy received antidisialoganglioside… 
Highly Cited
2011
Highly Cited
2011
Human Vγ2 Vδ2-bearing T cells have recently received much attention in cancer immunotherapy. In this study, we conducted a phase… 
Highly Cited
2007
Highly Cited
2007
PurposeAlthough various types of immunotherapy have been used to improve the prognosis of patients with advanced renal cell… 
2000
2000
se of drug eruption after long term rIL-2 therapy is reported.A 67-year-old man had a tumor on his right temporal scalp on June… 
Review
1993
Review
1993
SynopsisRecombinant interleukin-2 (IL-2) products (e.g. aldesleukin, teceleukin) are nonglycosylated, modified forms of the… 
Review
1991
Review
1991
The chemical properties, pharmacology, immunology, pharmacokinetics, clinical trials, adverse effects, and dosage and… 
1991
1991
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin‐2 (IL‐2… 
1991
1991
Fifteen patients with advanced, measurable renal cell carcinoma entered a Phase II clinical trial of interleukin-2 (IL-2… 
1989
1989
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or… 
1989
1989
Single doses of teceleukin ranging from 0.1 to 30 x 10(6) units were administered to cancer patients as intravenous infusions or…